Isotope technology developer Eckert & Ziegler has agreed to provide financial backing for the development of two new radiopharmaceuticals for diagnosing and treating lymphoma.
The company said it will initially pay 3 million euros as part of an option agreement, which may lead in the coming years to further annual payments of 2 million to 3 million euros if milestones are met. These funds will support the production of pharmaceutical-grade material for phase I trials that have already been prepared by two investigator-led academic consortia in France and Germany targeting several forms of myeloma and lymphatic leukemia.
In addition, the money will be used for the clinical development of a complementary diagnostic radiopharmaceutical labeled with gallium-68, the firm said.
